Advances in gene therapy have shed light on the experimental treatment of AD, and molecules, such as NGF, MAPT, APP, TRIM11, TREM2 and apoE, which play critical roles in the onset and progression of AD, may serve as promising therapeutic targets (Nagahara et al., 2009; Scheltens et al., 2021; Strang et al., 2019; Zhang et al., 2023). This evidence concerns the gene NGF and Alzheimer disease.